Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of THN102 in Parkinson's Disease with Excessive Daytime Sleepiness
NCT03624920Phase 2Completed
- Sponsor
- Theranexus
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of THN102 in Excessive Daytime Sleepiness (EDS), sponsored by Theranexus. Started Jul 2018; status: completed.
02
Drugs
THN102
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT03624920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624920.